Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Effect of the incretin hormones on the endocrine pancreas in end-stage renal disease

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Increases in bioactive IGF do not parallel increases in total IGF-I during growth hormone treatment of children born SGA

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Muscle-liver substrate fluxes in exercising humans and potential effects on hepatic metabolism

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. A Polygenic Risk Score Suggests Shared Genetic Architecture of Voice Break With Early Markers of Pubertal Onset in Boys

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Effect of dosage of 17ß-estradiol on uterine growth in Turner syndrome - a randomized controlled clinical pilot trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Gestational Diabetes Risk in Migrants. A Nationwide, Register-Based Study of all Births in Denmark 2004 to 2015

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Effects of Gender-Affirming Hormone Therapy on Insulin Sensitivity and Incretin Responses in Transgender People

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

CONTEXT: The insulin-stimulating and glucagon-regulating effects of the two incretin hormones, glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), contribute to maintain normal glucose homeostasis. Impaired glucose tolerance (IGT) occurs with high prevalence among patients with end-stage renal disease (ESRD).

OBJECTIVE: To evaluate the effect of the incretin hormones on endocrine pancreatic function in patients with ESRD.

DESIGN: and Setting: Twelve ESRD patients on chronic haemodialysis and 12 matched healthy controls, all with normal oral glucose tolerance test, were included. On three separate days, a 2 h euglycaemic clamp followed by a 2 h hyperglycaemic clamp (3 mM above fasting level) was performed with concomitant infusion of GLP-1 (1 pmol/kg/min), GIP (2 pmol/kg/min) or saline administered in a randomised, double-blinded fashion. A 30% lower infusion rate was used in the ESRD group to obtain comparable incretin hormone plasma levels.

RESULTS: During clamps, comparable plasma glucose and intact incretin hormone concentrations were achieved. The effect of GLP-1 to increase insulin concentrations relative to placebo levels tended to be lower during euglycaemia in ESRD and was significantly reduced during hyperglycaemia (50 [8-72]%, P=0.03). Similarly, the effect of GIP relative to placebo levels tended to be lower during euglycaemia in ESRD and was significantly reduced during hyperglycaemia (34 [13-50]%, P=0.005). Glucagon was suppressed in both groups with controls reaching lower concentrations than ESRD patients.

CONCLUSIONS: The effect of incretin hormones to increase insulin release is reduced in ESRD which together with elevated glucagon levels could contribute to the high prevalence of IGT among ESRD patients.

OriginalsprogEngelsk
Artikelnummerdgz048
TidsskriftThe Journal of clinical endocrinology and metabolism
Vol/bind105
Udgave nummer1
ISSN0021-972X
DOI
StatusUdgivet - jan. 2020

Bibliografisk note

© Endocrine Society 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

ID: 58130589